Polyoxometalates—Potent and selective ecto-nucleotidase inhibitors
Polyoxometalates (POMs) are inorganic cluster metal complexes that possess versatile biological activities, including antibacterial, anticancer, antidiabetic, and antiviral effects. Their mechanisms of action at the molecular level are largely unknown. However, it has been suggested that the inhibit...
Gespeichert in:
Veröffentlicht in: | Biochemical pharmacology 2015-01, Vol.93 (2), p.171-181 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 181 |
---|---|
container_issue | 2 |
container_start_page | 171 |
container_title | Biochemical pharmacology |
container_volume | 93 |
creator | Lee, Sang-Yong Fiene, Amelie Li, Wenjin Hanck, Theodor Brylev, Konstantin A. Fedorov, Vladimir E. Lecka, Joanna Haider, Ali Pietzsch, Hans-Jürgen Zimmermann, Herbert Sévigny, Jean Kortz, Ulrich Stephan, Holger Müller, Christa E. |
description | Polyoxometalates (POMs) are inorganic cluster metal complexes that possess versatile biological activities, including antibacterial, anticancer, antidiabetic, and antiviral effects. Their mechanisms of action at the molecular level are largely unknown. However, it has been suggested that the inhibition of several enzyme families (e.g., phosphatases, protein kinases or ecto-nucleotidases) by POMs may contribute to their pharmacological properties. Ecto-nucleotidases are cell membrane-bound or secreted glycoproteins involved in the hydrolysis of extracellular nucleotides thereby regulating purinergic (and pyrimidinergic) signaling. They comprise four distinct families: ecto-nucleoside triphosphate diphosphohydrolases (NTPDases), ecto-nucleotide pyrophosphatases/phosphodiesterases (NPPs), alkaline phosphatases (APs) and ecto-5′-nucleotidase (eN). In the present study, we evaluated the inhibitory potency of a series of polyoxometalates as well as chalcogenide hexarhenium cluster complexes at a broad range of ecto-nucleotidases. [Co4(H2O)2(PW9O34)2]10− (5, PSB-POM142) was discovered to be the most potent inhibitor of human NTPDase1 described so far (Ki: 3.88nM). Other investigated POMs selectively inhibited human NPP1, [TiW11CoO40]8− (4, PSB-POM141, Ki: 1.46nM) and [NaSb9W21O86]18− (6, PSB-POM143, Ki: 4.98nM) representing the most potent and selective human NPP1 inhibitors described to date. [NaP5W30O110]14− (8, PSB-POM144) strongly inhibited NTPDase1–3 and NPP1 and may therefore be used as a pan-inhibitor to block ATP hydrolysis. The polyoxoanionic compounds displayed a non-competitive mechanism of inhibition of NPPs and eN, but appeared to be competitive inhibitors of TNAP. Future in vivo studies with selected inhibitors identified in the current study are warranted. |
doi_str_mv | 10.1016/j.bcp.2014.11.002 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1645779284</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006295214006595</els_id><sourcerecordid>1645779284</sourcerecordid><originalsourceid>FETCH-LOGICAL-c353t-372d3ced65f5b0646ef613ac3df69dd2f0d0372ba8ab20f1553d0551569449153</originalsourceid><addsrcrecordid>eNp9kEtOwzAQhi0EouVxADaoSzYJHjt2E7FC5SlVogtYW449Ea7SuMRuBTsOwQk5Ca5aWLKaGembXzMfIWdAc6AgL-d5bZY5o1DkADmlbI8MoRzzjFWy3CdDSqlMvWADchTCfDOWEg7JgImiqEQlh-Rm5tsP_-4XGHWrI4bvz6-Zj9jFke7sKGCLJro1jlLxWbcyLfrorA44ct2rq130fTghB41uA57u6jF5ubt9njxk06f7x8n1NDNc8JjxMbPcoJWiETWVhcRGAteG20ZW1rKGWpqYWpe6ZrQBIbilQoCQVToXBD8mF9vcZe_fVhiiWrhgsG11h34VFMhCjMcVK4uEwhY1vQ-hx0Yte7fQ_YcCqjby1FwleWojTwGoJC_tnO_iV_UC7d_Gr60EXG0BTE-uHfYqGIddesn1yY-y3v0T_wMgGICa</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1645779284</pqid></control><display><type>article</type><title>Polyoxometalates—Potent and selective ecto-nucleotidase inhibitors</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Lee, Sang-Yong ; Fiene, Amelie ; Li, Wenjin ; Hanck, Theodor ; Brylev, Konstantin A. ; Fedorov, Vladimir E. ; Lecka, Joanna ; Haider, Ali ; Pietzsch, Hans-Jürgen ; Zimmermann, Herbert ; Sévigny, Jean ; Kortz, Ulrich ; Stephan, Holger ; Müller, Christa E.</creator><creatorcontrib>Lee, Sang-Yong ; Fiene, Amelie ; Li, Wenjin ; Hanck, Theodor ; Brylev, Konstantin A. ; Fedorov, Vladimir E. ; Lecka, Joanna ; Haider, Ali ; Pietzsch, Hans-Jürgen ; Zimmermann, Herbert ; Sévigny, Jean ; Kortz, Ulrich ; Stephan, Holger ; Müller, Christa E.</creatorcontrib><description>Polyoxometalates (POMs) are inorganic cluster metal complexes that possess versatile biological activities, including antibacterial, anticancer, antidiabetic, and antiviral effects. Their mechanisms of action at the molecular level are largely unknown. However, it has been suggested that the inhibition of several enzyme families (e.g., phosphatases, protein kinases or ecto-nucleotidases) by POMs may contribute to their pharmacological properties. Ecto-nucleotidases are cell membrane-bound or secreted glycoproteins involved in the hydrolysis of extracellular nucleotides thereby regulating purinergic (and pyrimidinergic) signaling. They comprise four distinct families: ecto-nucleoside triphosphate diphosphohydrolases (NTPDases), ecto-nucleotide pyrophosphatases/phosphodiesterases (NPPs), alkaline phosphatases (APs) and ecto-5′-nucleotidase (eN). In the present study, we evaluated the inhibitory potency of a series of polyoxometalates as well as chalcogenide hexarhenium cluster complexes at a broad range of ecto-nucleotidases. [Co4(H2O)2(PW9O34)2]10− (5, PSB-POM142) was discovered to be the most potent inhibitor of human NTPDase1 described so far (Ki: 3.88nM). Other investigated POMs selectively inhibited human NPP1, [TiW11CoO40]8− (4, PSB-POM141, Ki: 1.46nM) and [NaSb9W21O86]18− (6, PSB-POM143, Ki: 4.98nM) representing the most potent and selective human NPP1 inhibitors described to date. [NaP5W30O110]14− (8, PSB-POM144) strongly inhibited NTPDase1–3 and NPP1 and may therefore be used as a pan-inhibitor to block ATP hydrolysis. The polyoxoanionic compounds displayed a non-competitive mechanism of inhibition of NPPs and eN, but appeared to be competitive inhibitors of TNAP. Future in vivo studies with selected inhibitors identified in the current study are warranted.</description><identifier>ISSN: 0006-2952</identifier><identifier>EISSN: 1873-2968</identifier><identifier>DOI: 10.1016/j.bcp.2014.11.002</identifier><identifier>PMID: 25449596</identifier><language>eng</language><publisher>England: Elsevier Inc</publisher><subject>Adenosine Triphosphatases - antagonists & inhibitors ; Adenosine Triphosphatases - metabolism ; Alkaline phosphatase ; Animals ; Cell Line, Tumor ; Dose-Response Relationship, Drug ; Ecto-5′-nucleotidase ; Ecto-nucleotidase inhibitor ; Enzyme Inhibitors - metabolism ; Enzyme Inhibitors - pharmacology ; Humans ; Insecta ; Mice ; NPP1 ; NTPDase1 ; Phosphoric Diester Hydrolases - metabolism ; Polyoxometalate ; Sf9 Cells ; Tungsten Compounds - metabolism ; Tungsten Compounds - pharmacology</subject><ispartof>Biochemical pharmacology, 2015-01, Vol.93 (2), p.171-181</ispartof><rights>2014 Elsevier Inc.</rights><rights>Copyright © 2014 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c353t-372d3ced65f5b0646ef613ac3df69dd2f0d0372ba8ab20f1553d0551569449153</citedby><cites>FETCH-LOGICAL-c353t-372d3ced65f5b0646ef613ac3df69dd2f0d0372ba8ab20f1553d0551569449153</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.bcp.2014.11.002$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25449596$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lee, Sang-Yong</creatorcontrib><creatorcontrib>Fiene, Amelie</creatorcontrib><creatorcontrib>Li, Wenjin</creatorcontrib><creatorcontrib>Hanck, Theodor</creatorcontrib><creatorcontrib>Brylev, Konstantin A.</creatorcontrib><creatorcontrib>Fedorov, Vladimir E.</creatorcontrib><creatorcontrib>Lecka, Joanna</creatorcontrib><creatorcontrib>Haider, Ali</creatorcontrib><creatorcontrib>Pietzsch, Hans-Jürgen</creatorcontrib><creatorcontrib>Zimmermann, Herbert</creatorcontrib><creatorcontrib>Sévigny, Jean</creatorcontrib><creatorcontrib>Kortz, Ulrich</creatorcontrib><creatorcontrib>Stephan, Holger</creatorcontrib><creatorcontrib>Müller, Christa E.</creatorcontrib><title>Polyoxometalates—Potent and selective ecto-nucleotidase inhibitors</title><title>Biochemical pharmacology</title><addtitle>Biochem Pharmacol</addtitle><description>Polyoxometalates (POMs) are inorganic cluster metal complexes that possess versatile biological activities, including antibacterial, anticancer, antidiabetic, and antiviral effects. Their mechanisms of action at the molecular level are largely unknown. However, it has been suggested that the inhibition of several enzyme families (e.g., phosphatases, protein kinases or ecto-nucleotidases) by POMs may contribute to their pharmacological properties. Ecto-nucleotidases are cell membrane-bound or secreted glycoproteins involved in the hydrolysis of extracellular nucleotides thereby regulating purinergic (and pyrimidinergic) signaling. They comprise four distinct families: ecto-nucleoside triphosphate diphosphohydrolases (NTPDases), ecto-nucleotide pyrophosphatases/phosphodiesterases (NPPs), alkaline phosphatases (APs) and ecto-5′-nucleotidase (eN). In the present study, we evaluated the inhibitory potency of a series of polyoxometalates as well as chalcogenide hexarhenium cluster complexes at a broad range of ecto-nucleotidases. [Co4(H2O)2(PW9O34)2]10− (5, PSB-POM142) was discovered to be the most potent inhibitor of human NTPDase1 described so far (Ki: 3.88nM). Other investigated POMs selectively inhibited human NPP1, [TiW11CoO40]8− (4, PSB-POM141, Ki: 1.46nM) and [NaSb9W21O86]18− (6, PSB-POM143, Ki: 4.98nM) representing the most potent and selective human NPP1 inhibitors described to date. [NaP5W30O110]14− (8, PSB-POM144) strongly inhibited NTPDase1–3 and NPP1 and may therefore be used as a pan-inhibitor to block ATP hydrolysis. The polyoxoanionic compounds displayed a non-competitive mechanism of inhibition of NPPs and eN, but appeared to be competitive inhibitors of TNAP. Future in vivo studies with selected inhibitors identified in the current study are warranted.</description><subject>Adenosine Triphosphatases - antagonists & inhibitors</subject><subject>Adenosine Triphosphatases - metabolism</subject><subject>Alkaline phosphatase</subject><subject>Animals</subject><subject>Cell Line, Tumor</subject><subject>Dose-Response Relationship, Drug</subject><subject>Ecto-5′-nucleotidase</subject><subject>Ecto-nucleotidase inhibitor</subject><subject>Enzyme Inhibitors - metabolism</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>Humans</subject><subject>Insecta</subject><subject>Mice</subject><subject>NPP1</subject><subject>NTPDase1</subject><subject>Phosphoric Diester Hydrolases - metabolism</subject><subject>Polyoxometalate</subject><subject>Sf9 Cells</subject><subject>Tungsten Compounds - metabolism</subject><subject>Tungsten Compounds - pharmacology</subject><issn>0006-2952</issn><issn>1873-2968</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEtOwzAQhi0EouVxADaoSzYJHjt2E7FC5SlVogtYW449Ea7SuMRuBTsOwQk5Ca5aWLKaGembXzMfIWdAc6AgL-d5bZY5o1DkADmlbI8MoRzzjFWy3CdDSqlMvWADchTCfDOWEg7JgImiqEQlh-Rm5tsP_-4XGHWrI4bvz6-Zj9jFke7sKGCLJro1jlLxWbcyLfrorA44ct2rq130fTghB41uA57u6jF5ubt9njxk06f7x8n1NDNc8JjxMbPcoJWiETWVhcRGAteG20ZW1rKGWpqYWpe6ZrQBIbilQoCQVToXBD8mF9vcZe_fVhiiWrhgsG11h34VFMhCjMcVK4uEwhY1vQ-hx0Yte7fQ_YcCqjby1FwleWojTwGoJC_tnO_iV_UC7d_Gr60EXG0BTE-uHfYqGIddesn1yY-y3v0T_wMgGICa</recordid><startdate>20150115</startdate><enddate>20150115</enddate><creator>Lee, Sang-Yong</creator><creator>Fiene, Amelie</creator><creator>Li, Wenjin</creator><creator>Hanck, Theodor</creator><creator>Brylev, Konstantin A.</creator><creator>Fedorov, Vladimir E.</creator><creator>Lecka, Joanna</creator><creator>Haider, Ali</creator><creator>Pietzsch, Hans-Jürgen</creator><creator>Zimmermann, Herbert</creator><creator>Sévigny, Jean</creator><creator>Kortz, Ulrich</creator><creator>Stephan, Holger</creator><creator>Müller, Christa E.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20150115</creationdate><title>Polyoxometalates—Potent and selective ecto-nucleotidase inhibitors</title><author>Lee, Sang-Yong ; Fiene, Amelie ; Li, Wenjin ; Hanck, Theodor ; Brylev, Konstantin A. ; Fedorov, Vladimir E. ; Lecka, Joanna ; Haider, Ali ; Pietzsch, Hans-Jürgen ; Zimmermann, Herbert ; Sévigny, Jean ; Kortz, Ulrich ; Stephan, Holger ; Müller, Christa E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c353t-372d3ced65f5b0646ef613ac3df69dd2f0d0372ba8ab20f1553d0551569449153</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adenosine Triphosphatases - antagonists & inhibitors</topic><topic>Adenosine Triphosphatases - metabolism</topic><topic>Alkaline phosphatase</topic><topic>Animals</topic><topic>Cell Line, Tumor</topic><topic>Dose-Response Relationship, Drug</topic><topic>Ecto-5′-nucleotidase</topic><topic>Ecto-nucleotidase inhibitor</topic><topic>Enzyme Inhibitors - metabolism</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>Humans</topic><topic>Insecta</topic><topic>Mice</topic><topic>NPP1</topic><topic>NTPDase1</topic><topic>Phosphoric Diester Hydrolases - metabolism</topic><topic>Polyoxometalate</topic><topic>Sf9 Cells</topic><topic>Tungsten Compounds - metabolism</topic><topic>Tungsten Compounds - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lee, Sang-Yong</creatorcontrib><creatorcontrib>Fiene, Amelie</creatorcontrib><creatorcontrib>Li, Wenjin</creatorcontrib><creatorcontrib>Hanck, Theodor</creatorcontrib><creatorcontrib>Brylev, Konstantin A.</creatorcontrib><creatorcontrib>Fedorov, Vladimir E.</creatorcontrib><creatorcontrib>Lecka, Joanna</creatorcontrib><creatorcontrib>Haider, Ali</creatorcontrib><creatorcontrib>Pietzsch, Hans-Jürgen</creatorcontrib><creatorcontrib>Zimmermann, Herbert</creatorcontrib><creatorcontrib>Sévigny, Jean</creatorcontrib><creatorcontrib>Kortz, Ulrich</creatorcontrib><creatorcontrib>Stephan, Holger</creatorcontrib><creatorcontrib>Müller, Christa E.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Biochemical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lee, Sang-Yong</au><au>Fiene, Amelie</au><au>Li, Wenjin</au><au>Hanck, Theodor</au><au>Brylev, Konstantin A.</au><au>Fedorov, Vladimir E.</au><au>Lecka, Joanna</au><au>Haider, Ali</au><au>Pietzsch, Hans-Jürgen</au><au>Zimmermann, Herbert</au><au>Sévigny, Jean</au><au>Kortz, Ulrich</au><au>Stephan, Holger</au><au>Müller, Christa E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Polyoxometalates—Potent and selective ecto-nucleotidase inhibitors</atitle><jtitle>Biochemical pharmacology</jtitle><addtitle>Biochem Pharmacol</addtitle><date>2015-01-15</date><risdate>2015</risdate><volume>93</volume><issue>2</issue><spage>171</spage><epage>181</epage><pages>171-181</pages><issn>0006-2952</issn><eissn>1873-2968</eissn><abstract>Polyoxometalates (POMs) are inorganic cluster metal complexes that possess versatile biological activities, including antibacterial, anticancer, antidiabetic, and antiviral effects. Their mechanisms of action at the molecular level are largely unknown. However, it has been suggested that the inhibition of several enzyme families (e.g., phosphatases, protein kinases or ecto-nucleotidases) by POMs may contribute to their pharmacological properties. Ecto-nucleotidases are cell membrane-bound or secreted glycoproteins involved in the hydrolysis of extracellular nucleotides thereby regulating purinergic (and pyrimidinergic) signaling. They comprise four distinct families: ecto-nucleoside triphosphate diphosphohydrolases (NTPDases), ecto-nucleotide pyrophosphatases/phosphodiesterases (NPPs), alkaline phosphatases (APs) and ecto-5′-nucleotidase (eN). In the present study, we evaluated the inhibitory potency of a series of polyoxometalates as well as chalcogenide hexarhenium cluster complexes at a broad range of ecto-nucleotidases. [Co4(H2O)2(PW9O34)2]10− (5, PSB-POM142) was discovered to be the most potent inhibitor of human NTPDase1 described so far (Ki: 3.88nM). Other investigated POMs selectively inhibited human NPP1, [TiW11CoO40]8− (4, PSB-POM141, Ki: 1.46nM) and [NaSb9W21O86]18− (6, PSB-POM143, Ki: 4.98nM) representing the most potent and selective human NPP1 inhibitors described to date. [NaP5W30O110]14− (8, PSB-POM144) strongly inhibited NTPDase1–3 and NPP1 and may therefore be used as a pan-inhibitor to block ATP hydrolysis. The polyoxoanionic compounds displayed a non-competitive mechanism of inhibition of NPPs and eN, but appeared to be competitive inhibitors of TNAP. Future in vivo studies with selected inhibitors identified in the current study are warranted.</abstract><cop>England</cop><pub>Elsevier Inc</pub><pmid>25449596</pmid><doi>10.1016/j.bcp.2014.11.002</doi><tpages>11</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0006-2952 |
ispartof | Biochemical pharmacology, 2015-01, Vol.93 (2), p.171-181 |
issn | 0006-2952 1873-2968 |
language | eng |
recordid | cdi_proquest_miscellaneous_1645779284 |
source | MEDLINE; Elsevier ScienceDirect Journals Complete |
subjects | Adenosine Triphosphatases - antagonists & inhibitors Adenosine Triphosphatases - metabolism Alkaline phosphatase Animals Cell Line, Tumor Dose-Response Relationship, Drug Ecto-5′-nucleotidase Ecto-nucleotidase inhibitor Enzyme Inhibitors - metabolism Enzyme Inhibitors - pharmacology Humans Insecta Mice NPP1 NTPDase1 Phosphoric Diester Hydrolases - metabolism Polyoxometalate Sf9 Cells Tungsten Compounds - metabolism Tungsten Compounds - pharmacology |
title | Polyoxometalates—Potent and selective ecto-nucleotidase inhibitors |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T20%3A11%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Polyoxometalates%E2%80%94Potent%20and%20selective%20ecto-nucleotidase%20inhibitors&rft.jtitle=Biochemical%20pharmacology&rft.au=Lee,%20Sang-Yong&rft.date=2015-01-15&rft.volume=93&rft.issue=2&rft.spage=171&rft.epage=181&rft.pages=171-181&rft.issn=0006-2952&rft.eissn=1873-2968&rft_id=info:doi/10.1016/j.bcp.2014.11.002&rft_dat=%3Cproquest_cross%3E1645779284%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1645779284&rft_id=info:pmid/25449596&rft_els_id=S0006295214006595&rfr_iscdi=true |